Clinical trials: Exacerbations
Cardiovascular Diseases
Smart Wearable Insights to Prevent Exacerbations and Recurrence - Rehabilitation Study: SWIPER-REHAB
Aims of the study: To measure the rate of completion of a digital cardiac rehabilitation programme at Imperial College Healthcare NHS Trust (ICHNT) To measure the health economic impact of a digital cardiac rehabilitation…
- Trial name
- SWIPER-REHAB (NCT06011395)
- Testing
- Smartwatch, Imperial Healthy Hearts app
- Where
- United Kingdom
- Volunteers
- 1,800 people
- Sponsor
- Imperial College London
COPD Exacerbation
Molecular Breath Print of COPD Patients With Exacerbations Despite Triple Inhalational Therapy
Determination of specific molecular breath patterns by secondary electrospray ionization mass spectrometry (SESIHRMS) during and 8 weeks after a COPD exacerbation.
- Trial name
- TripleEX (NCT04638920)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 35 people
- Sponsor
- Malcolm Kohler
Chronic Obstructive Pulmonary Disease (COPD), Inflammatory Disease
Endothelial Dysfunction in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to determine a possible association between the clinical entity of exacerbation, markers of systemic inflammation and endothelial dysfunction in patients with COPD.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Inflammatory Disease, Endothelial Dysfunction
- Trial name
- EDAECOPD (NCT01460082)
- Where
- Austria
- Volunteers
- 29 people
- Sponsor
- LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology
Bronchial Asthma, Status Asthmaticus
NiPPV in the Treatment of Acute Asthma Exacerbations
Study Summary: Title: A Randomized Controlled Trial of Noninvasive Positive Airway Pressure in the Pediatric Emergency Department for the Treatment of Acute Asthma Exacerbations Principal Investigator: Thomas J.
- Trial name
- NCT03219736
- Testing
- Standard of Care therapies, NiPPV Therapy, Routine Respiratory Care
- Where
- United States
- Sponsor
- Arkansas Children's Hospital Research Institute
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-centered, randomized, placebo-controlled, double-blind, parallel group, trial evaluating 2 doses of mepolizumab against placebo given every 4 weeks through subcutaneous (SC) injection.
- Trial name
- NCT02105961
- Testing
- Mepolizumab
- Where
- 169 sites in United States, Argentina and 13 more
- Volunteers
- 674 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Promoting Activity After COPD Exacerbations, Aim 2
This randomized controlled pilot study involving patients with chronic obstructive pulmonary disease (COPD) recently discharged from the hospital will evaluate the feasibility and efficacy of a home-based mobile-health supported…
- Trial name
- PACE2 (NCT03793192)
- Testing
- PACE2 Intervention
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Illinois at Chicago
Chronic Obstructive Pulmonary Disease, Takotsubo Cardiomyopathy
Cardiac Assessment and Takotsubo-stunning Among COPD-exacerbations In-Hospital
The goal of this prospective observational study is to investigate to what extent acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) triggers Takotsubo-stunning, and how this affects the outcome for these…
- Conditions
- Chronic Obstructive Pulmonary Disease, Takotsubo Cardiomyopathy, Acute Heart Failure
- Trial name
- CATCH (NCT06597331)
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Sahlgrenska University Hospital
Chronic Obstructive Pulmonary Disease (COPD)
Study of Patient With Frequent COPD Exacerbations
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent…
- Trial name
- PRIORITY-COPD (NCT07221981)
- Where
- 30 sites in Russia
- Volunteers
- 2,024 people
- Sponsor
- AstraZeneca
Asthma Attack
Phenotyping and Classifying Asthma Exacerbations
An observational study in patients between 12 and 70 years old with an acute asthma exacerbation, to determine the relation between phenotypical characteristics and the treatment response.
- Trial name
- ExCluSieF (NCT05304039)
- Testing
- Questionnaires, Spirometry, Fractional Exhaled Nitric Oxide (FeNO)
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Franciscus Gasthuis
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
This trial is a randomized, double-blind, parallel-group, multicenter study to be conducted in the United States. The purpose of the study is to evaluate the rate of exacerbations of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT01110200
- Testing
- ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID
- Where
- 103 sites in United States, Argentina and 1 more
- Volunteers
- 639 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Chronic Airway Disease, Mucus Rheology and Exacerbations
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe…
- Trial name
- COPD-CARhE (NCT04339270)
- Testing
- Azithropycin according to symptoms, Azithromycin according to rheology or symptoms
- Where
- 3 sites in France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Montpellier
Asthma
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an…
- Trial name
- SWIFT-1 (NCT04719832)
- Testing
- GSK3511294 (Depemokimab)
- Where
- 123 sites in United States, Canada and 10 more
- Volunteers
- 395 people
- Sponsor
- GlaxoSmithKline
Severe Respiratory Exacerbation
Respiratory Exacerbations in Children With Bronchopulmonary Dysplasia (BPD): A Case-Control Study
This is an ambispective observational case-control study evaluating respiratory exacerbations in pediatric patients affected by bronchopulmonary dysplasia (BPD) compared with children without BPD.
- Trial name
- BPD-CC25 (NCT07666438)
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Pulmonary Disease, Chronic Obstructive
Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations
This was a retrospective cohort design using administrative claims data from Jan 1, 2003 through Sep 30, 2007, representing the years of available data, were used for this study.
- Trial name
- NCT01381406
- Testing
- TIO, TIO+FSC
- Volunteers
- 3,333 people
- Sponsor
- GlaxoSmithKline
Interstitial Lung Disease (ILD), Pulmonary Fibrosis
Interstitial Lung Disease Exacerbations Study
Interstitial lung disease (ILD) is an umbrella term covering numerous conditions that affect the lung tissue, interfering with the ability of the lungs to take up oxygen.
- Trial name
- INDEX (NCT06685874)
- Where
- 3 sites in United Kingdom
- Volunteers
- 1,500 people
- Sponsor
- Royal Devon and Exeter NHS Foundation Trust
Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation
Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER
The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).
- Trial name
- UTAPE BPCO (NCT01857947)
- Testing
- AECOPD Mr proADM
- Where
- 2 sites in France
- Volunteers
- 370 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Asthma, COPD
Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)
Exacerbations of asthma and COPD are an important cause of hospital admission and the main cause of annual winter bed shortages.
- Trial name
- ABRA (NCT04098718)
- Testing
- Benralizumab, Prednisolone
- Where
- United Kingdom
- Volunteers
- 158 people
- Sponsor
- University of Oxford
Chronic Obstructive Pulmonary Disease (COPD)
Targeted Retreatment of COPD Exacerbations
This study investigates the effects of targeted re-treatment of patients who do not recover from an exacerbation of COPD. Half of the patients will receive ciprofloxacin while the other half will receive a placebo.
- Trial name
- NCT02300220
- Testing
- Ciprofloxacin
- Where
- 4 sites in United Kingdom
- Volunteers
- 144 people
- Sponsor
- Imperial College London
Acute Bronchitis, Acute Exacerbations of Chronic Bronchitis
A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)
The purpose of this study is to determine the optimal dose of HL301 in patients with acute bronchitis or acute exacerbations of chronic bronchitis.
- Trial name
- HL301 (NCT02250027)
- Testing
- HL301 300mg capsule
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Exacerbation of COPD
Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD
Chronic obstructive pulmonary disease (COPD) is highly prevalent and frequently punctuated by severe acute exacerbations (AECOPD), defined as a temporary worsening of symptoms which leads to hospitalisation.
- Trial name
- NCT05480566
- Testing
- Functional strength training, NMES, Daily medical treatment (e.g., oxygen, medrol, duovent, azitromycine)
- Where
- Belgium
- Volunteers
- 35 people
- Sponsor
- Hasselt University